Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany

References

• Cohen JI. Herpes zoster. N Engl J Med. 2013;369(3):255–63. doi:10.1056/NEJMcp1302674.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier P, Wollan PC, Sauver JLS, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–49.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7(11):1581–95. doi:10.1586/14737175.7.11.1581.
   PubMedGoogle Scholar
• Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2013;14:1015–26.
   PubMed Web of Science ®Google Scholar
• German Standing Committee on Vaccination at the Robert Koch I. Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017;60(10):1162–79. doi:10.1007/s00103-017-2618-6.
   PubMed Web of Science ®Google Scholar
• Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16(2):265–71. doi:10.1517/14712598.2016.1134481.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.
   PubMed Web of Science ®Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu C-J, Andrews C, Beytout J, Caso C, Cheng H-S, Cheong HJ, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase III clinical trials (ZOE-50 and ZOE-70). Clin Infect Dis. 2021;ciab629. Online ahead of print. doi:10.1093/cid/ciab629.
   Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, Von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13:2213–21.
   PubMed Web of Science ®Google Scholar
• Anastassopoulou A, Van Oorschot D, Poulsen Nautrup B, Varghese L, Von Krempelhuber A, Neine M, Lorenc S, Curran D. PIN53 - is the recombinant zoster vaccine also cost-effective for the German population ≥50 years of age? Value Health. 2018;21:S230. doi:10.1016/j.jval.2018.09.1372.
   Web of Science ®Google Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, Von Krempelhuber A, Neine M, Lorenc S, Curran D. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2019;15:34–44.
   PubMed Web of Science ®Google Scholar
• Siedler A, Koch J, Garbe E, Hengel H, Von Kries R, Ledig T, Mertens T, Zepp F, Überla K. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(3):352–76. doi:10.1007/s00103-019-02882-5.
   PubMed Web of Science ®Google Scholar
• Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton (FL): Chapman & Hall CRC; 1993.
   Google Scholar
• Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen L-A, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M. Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model. PharmacoEconomics. 2016;34:1299–308.
   PubMed Web of Science ®Google Scholar
• Scholz SM, Weidemann F, Damm O, Ultsch B, Greiner W, Wichmann O. Cost-effectiveness of routine childhood vaccination against seasonal influenza in Germany. Value Health. 2021;24:32–40.
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–08.
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248–58. doi:10.1001/jamainternmed.2017.7431.
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Aljassem A, Stassinopoulos J, Pisacreta G, Hutton D, and Cost-effectiveness A. Analysis of an adjuvanted subunit vaccine for the prevention of herpes zoster and post-herpetic neuralgia. Open Forum Infec Dis. 2019;6(7): ofz219. https://doi.org/10.1093/ofid/ofz219
   PubMed Web of Science ®Google Scholar
• Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380–88. doi:10.7326/M18-2347.
   PubMed Web of Science ®Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. PharmacoEconomics. 2013;31:125–36.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290–308. doi:10.1177/027298902400448867.
   PubMed Web of Science ®Google Scholar
• Hastie A, Catteau G, Enemuo A, Mrkvan T, Salaun B, Volpe S, Smetana J, Rombo L, Schwarz T, Pauksens K, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. J Infect Dis. 2020. doi:10.1093/infdis/jiaa300.
   Web of Science ®Google Scholar
• Levin MJ, Weinberg A. Adjuvanted recombinant glycoprotein E herpes zoster vaccine. Clin Infect Dis. 2020;70(7):1509–15. doi:10.1093/cid/ciz770.
   PubMed Web of Science ®Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A. 2019;74(8):1231–38.
   Google Scholar
• Curran D, Matthews S, Rowley SD, Young J-AH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25(12):2474–81.
   PubMed Web of Science ®Google Scholar
• Bastidas A, de La Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33.
   PubMed Web of Science ®Google Scholar
• Patterson BJ, Chen -C-C, McGuiness CB, Glasser LI, Sun K, and Buck PO. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. Hum Vaccin Immunother. 2021;17(8): 2482–2487.
   PubMed Web of Science ®Google Scholar